| CPC A61B 5/398 (2021.01) [A61B 5/0036 (2018.08); A61B 5/0048 (2013.01); A61B 5/4836 (2013.01); A61B 5/4848 (2013.01); A61B 5/6821 (2013.01); A61B 5/7225 (2013.01); A61K 48/0058 (2013.01); A61K 48/0075 (2013.01); A61N 5/0622 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); A61N 2005/0652 (2013.01); A61N 2005/0661 (2013.01); A61N 2005/0663 (2013.01); C12N 2750/14132 (2013.01); C12N 2750/14143 (2013.01); C12N 2799/025 (2013.01); C12N 2830/008 (2013.01); C12N 2830/42 (2013.01); C12N 2840/44 (2013.01)] | 10 Claims |
|
1. An isolated nucleic acid expression vector comprising:
(a) a promoter region comprising an M opsin promoter comprising the nucleic acid sequence of SEQ ID NO: 2, wherein the promoter region is specific for primate retinal cone cells; and
(b) a gene encoding a therapeutic protein comprising the amino acid sequence of SEQ ID NO: 11, wherein the gene is operatively linked to the promoter region.
|